Morgan Stanley maintains overweight rating on Ranbaxy Labs

RELATED NEWS Buy Balmer Lawire & Co, target Rs 630: Bajaj Capital Buy Peninsula Land, target Rs 719: Enam Securities Hold Hero Honda, target Rs 837: Prime Broking Hold Peninsula Land, target Rs 672: Ambit Capital Mindtree an underperformer, tgt Rs 475: Karvy ALSO READ News and Notices about Ranbaxy Labs See interviews with Ranbaxy Labs Management See what other Experts & Brokerages are saying about Ranbaxy Labs See previous Results of Ranbaxy Labs Ranbaxy Labs BSE | NSE 10/02/12 Are Mutual Funds betting on Ranbaxy Labs?

Morgan Stanley is bullish on Ranbaxy Labs and has maintianed overweight rating on the stock with target price of Rs 447.

 

Morgan Stanley research report on Ranbaxy Laboratories

 

Diovan (valsartan, USD1.4 billion brand size, USD 2.5 billion including HCT) patent challenge court case between Novartis and Ranbaxy has been discontinued. Court case out of the way, this appears to us a potential 180 days exclusivity for Ranbaxy, likely to get triggered in Sep'12.

 

Patent Picture 

 

Diovan has three orange book listed patents - '578 (Sep'12 expiry), '990 (Oct'16) and '197 (Dec'17). Novartis did not litigate on '990 and '197 patents and the case has been settled with respect to '578 patent.

 

Commercialization Prospects 

 

We believe that the earliest Ranbaxy can monetize this opportunity is in Sep'12 with 180 days exclusivity. In our view, this could be a shared exclusivity with 1-2 additional players. Ranbaxy can potentially gross USD 130 -USD 200 million (depending on whether it is ftf on HCT as well, and number of players sharing the upside).

 

Stock Implication 

 

Given the distant commercialization prospects, this opportunity should not make a meaningful impact on the valuations now, we believe. However, for longer term investors, this opportunity highlights increasing depth in Ranbaxy's pipeline - a potential settlement in 2008, Valtrex by end 2009, Lipitor by mid 2010 (as case stands now), Diovan in 2012 etc. We reiterate our Overweight rating on the stock.